Oncosil Medical Ltd has released a press release.
OncoSil receives regulatory approval from Hong Kong
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from OncoSil Medical
- Appendix 4C - quarterly
- OncoSil Investor Update
- Appointment of Chief Executive Officer
- OncoSil FY21 half yearly review
- Termination of Mr Daniel Kenny as Chief Executive Officer
Later from OncoSil Medical
- OncoSil TGA regulatory update
- Receipt of $1.077m R&D Tax Incentive Refund
- 2021 AGM CEO Presentation
- PanCO Clinical Study on OncoSil Published in ESMO Open
- OncoSil approved for Innovation Funding (NUB) in Germany
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical